What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D.

We love to hear from our listeners. Send us a message. Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/